Congratulations to Regeneron for the FDA approval of their human IgG1 monoclonal antibody, Praluent (Alirocumab), as an injection for children with a genetic form of high cholesterol, heterozygous familial hypercholesterolemia (HeFH). ? Praluent works by inhibiting the binding of PCSK9 to the LDL receptor. PCSK9 regulates the number of LDL receptors you have, and thereby increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL-C levels in the blood. Read the press release here: https://lnkd.in/e9mJkqgb ? #Biointron #Antibodies #Immunotherapy #PharmaNews #FDA #Cholesterol
